Drug Regulators From 46 Countries To Participate In Upcoming Global Conclave In Greater Noida
Date
9/20/2022 2:07:59 PM
(MENAFN- KNN India)
Drug regulators from 46 countries to participate in upcoming global conclave in Greater Noida
New Delhi, Sept 20 (KNN) The Pharmaceutical Export Promotion Council (Pharmexcil) is organising the Global Regulators Conclave at India expo Centre in Greater Noida from September 21-23.
As per reports, drug regulators from over 46 countries will be participating in the conclave. Around 100 Indian regulatory officials are also expected to participate in the event.
During the event, the drug regulators will deliberate upon the need for mutual recognition of regulatory approvals for pharmaceutical products among these countries.
The participating drug regulators will primarily be from Africa, South America, CIS region and parts of Asia. These regions account for over 50 per cent of India's USD 24.6 billion pharmaceutical exports.
“The focus of the conclave is international regulatory convergence to promote accessibility and affordability of quality medicines”, Udaya Bhaskar, Director General, Pharmexcil, said.
“It is a niche event with exclusive one to one business meetings and deliberations with regulatory officials covering NAFTA, EU, Africa, ASEAN, CIS, LAC and WANA regions”, he added.
The conclave will have special discussions on the global expectations from India sourced generic drugs, learning from Covid-19 pandemic and the need for regulatory enablers for fast track approvals and supply changes resiliency, regulatory preparedness for healthcare emergencies, and the need for migration from routine to risk-based regulatory inspections to optimize human resources in the post-pandemic days.
The event is being supported by Ministry of commerce and Industry. (KNN Bureau)
MENAFN20092022000155011030ID1104896259
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.